
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,090 Listeners

30,718 Listeners

8,774 Listeners

26,264 Listeners

112,216 Listeners

56,586 Listeners

10,296 Listeners

5,202 Listeners

6,097 Listeners

556 Listeners

5,489 Listeners

10,185 Listeners

6,408 Listeners

2,020 Listeners

5,536 Listeners

4,366 Listeners

16,205 Listeners